When was GlycoPath founded?

GlycoPath was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is GlycoPath located?

GlycoPath is headquartered in Charleston, United States.

Is GlycoPath a funded company?

GlycoPath is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 17, 2019.

When was the latest funding round of GlycoPath?

GlycoPath's latest funding was a $***** Grant (prize money) round on Sep 15, 2023, with participation from 1 investor.

Where does GlycoPath rank among its competitors?

GlycoPath ranks 7th amongst 34 active competitors, of which 6 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Echelon Biosciences, which secured $399K in Sep, 2025.

Who are the top competitors of GlycoPath?

GlycoPath's top competitors include Iceni Glycoscience, Echelon Biosciences and GlyTech. Among them, Echelon Biosciences secured the most recent funding round in September, 2025.

GlycoPath - 2026 Company Profile, Team, Funding & Competitors

GlycoPath is a seed company based in Charleston (United States), founded in 2019. It operates as a Developer of glycan assays for biomarker discovery. GlycoPath has raised an undisclosed amount in funding from Bruker. The company has 34 active competitors, including 6 funded and 3 that have exited. Its top competitors include companies like Iceni Glycoscience, Echelon Biosciences and GlyTech.

Company Details

Developer of glycan assays for biomarker discovery. The assays utilize MALDI mass spectrometry imaging to study changes in the glycosylation of various disease states. The company has developed GlycoFibrotyper for the detection of liver fibrosis, in this N-linked glycans are released from antibody-captured glycoproteins and analyzed by MALDI-TOF mass spectrometry.

Key Metrics

Founded Year

2019

Location

Charleston, United States

Stage

Seed

Latest Funding Round

Grant (prize money), Sep 15, 2023, $*****

Investors

Bruker & 1 more

Ranked

7^th among 34 active competitors

Similar Companies

Iceni Glycoscience & 35 more

View GlycoPath's full profile

GlycoPath has raised funding over 4 rounds. Its first funding round was on Sep 17, 2019. Its latest funding round was a Grant (prize money) round on Sep 15, 2023 for $*****. 1 investor participated in its latest round. GlycoPath has 2 institutional investors.

Here is the list of recent funding rounds of GlycoPath:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 15, 2023	8216280	Grant (prize money)	9587938	1429610	5771119	6947234
Mar 01, 2022	8616759	Grant (prize money)	6589333	5085188	3909013	HHS
Mar 11, 2021	7326915	Seed	6110980	1448547	Bruker	5675642

Access funding benchmarks and valuations. Sign up today!

View details of GlycoPath's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GlycoPath include Iceni Glycoscience, Echelon Biosciences and GlyTech. Here is the list of Top 10 competitors of GlycoPath, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Iceni Glycoscience 2014, Norwich (United Kingdom), Seed	Provider of carbohydrate chemistry, glycobiology, and analytical services for diagnostics	$1.77M	New Anglia Local Enterprise Partnership, Europa	43/100
2nd	Echelon Biosciences 1997, Salt Lake City (United States), Acquired	Lipid and cell signaling solutions for diagnostics and drug treatments	-	National Science Foundation, NIH & 1 others	38/100
3rd	GlyTech 2012, Kyoto (Japan), Series B	Provider of human-type asparagine (Asp)-linked glycans for research applications	$9.14M	Yokogawa, Osaka University & 4 others	38/100
4th	GlycoSpot 2014, Frederiksberg (Denmark), Seed	Provider of solutions for high throughput enzyme screening	$3.58M	Capnova, Spring Nordic & 2 others	36/100
5th	ADDAX Biosciences 2017, Turin (Italy), Seed	Developer of a non-toxic formalin alternative tissue fixative. This fixative provides comparable or superior results to formalin in histological, immunohistochemical, and molecular analyses, while eliminating the carcinogenic and toxic risks associated with formalin use. The product is protected by an international patent and is designed for use in histology laboratories, improving both patient care and worker safety. The company collaborates with various research institutions to advance the application of this technology in different fields.	-	FT Partners, EIC Fund & 1 others	32/100
6th	GlycoScientific 2009, Athens (United States), Funding Raised	Glycobiology research reagents, antibodies, and standards for glycosylation characterization	-	Georgia Research Alliance, HHS	31/100
7th	GlycoPath 2019, Charleston (United States), Seed	Developer of glycan assays for biomarker discovery	-	Bruker, HHS	30/100
8th	TFChem 2007, Rouen (France), Funding Raised	Drug discovery platform exploiting fluoride chemistry to design glycomimetic compounds	-	Economy And Finance, Government of France ... & 4 others	29/100
9th	Avanti Polar Lipids 1969, Alabaster (United States), Acquired	High-purity lipid tools and solutions for cutting-edge research and pharmaceutical applications	-	-	28/100
10th	Elicityl 2002, Crolles (France), Seed	Oligo and polysaccharides for a wide range of industries	$137K	Succes Europe	26/100